The 2021-22 Leadership Development Program has 16 participants from various practice settings, subspecialties, and geographic locations.

Jennifer Eads, MDJennifer Eads, MD | University of Pennsylvania

Dr. Jennifer Eads is an Associate Professor of medicine and a GI oncologist at the University of Pennsylvania, Abramson Cancer Center. Her clinical and research interests focus on treatment strategies for patients with GI neuroendocrine tumors and esophagogastric cancers. She has been the principal investigator of multiple phase I/II/III clinical trials at both the institutional and national level. She is an active participant in the Eastern Cooperative Oncology Group (ECOG) where she is a member of the GI committee and is the chair of the neuroendocrine working group. She serves on the Board of Directors for the North American Neuroendocrine Tumor Society and her roles at Penn include serving as the Director of the Neuroendocrine Tumor Program, Physician Lead for GI Clinical Research and institutional ECOG PI.


Maria Monica Gramatges, MD, PhDMaria Monica Gramatges, MD, PhD | Baylor College of Medicine

Dr. Maria Gramatges is a pediatric hematologist/oncologist and Associate Professor of Pediatrics at Baylor College of Medicine. She co-directs the Texas Children’s Cancer and Hematology Centers’ Long-term Survivor Program, serves on the Outcomes-Survivorship Committee for the Children’s Oncology Group, and is the COG liaison for Passport for Care, a clinical decision support tool for developing and delivering Survivorship Care Plans. Dr. Gramatges is actively involved in the development of long-term follow-up guidelines for survivors of cancer diagnosed in childhood, adolescence, and young adulthood. Her clinical expertise is in treatment of childhood leukemias. Her research interests include the investigation of clinical, sociodemographic, and genetic/molecular predictors of late effects of childhood cancer treatment, particularly with respect to understanding cancer outcome disparities. She is currently a PI for a multi-institutional cohort building NIH grant, ‘Survivorship and Access to care for Latinos to Understand and address Disparities (SALUD).’


Erika Paige Hamilton, MDErika Paige Hamilton, MD | Sarah Cannon Research Institute /Tennessee Oncology

Dr. Erika Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a NCAA Postgraduate Scholarship. She then completed her medical degree and residency from University of North Carolina in Chapel Hill and fellowship training in oncology at Duke University. She joined Sarah Cannon Research Institute as investigator in drug development for women’s cancers in 2013. In 2015 she became the Director of the Breast and Gynecologic Cancer Research Program. She sees patients facing breast and gynecologic cancers from standard of care to phase II/III to phase I drug development.

Dr. Hamilton is the past Chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020. She serves on the Board of Directors for Susan G Komen middle Tennessee for 3 years running and is an Associate Editor for Clinical Breast Cancer. She was named to the Women to Watch Class of 2021 for Nashville Medical News.


Matthias Holdhoff, MD, PhDMatthias Holdhoff, MD, PhD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Dr. Matthias Holdhoff is an Associate Professor of Oncology, Neurology and Neurosurgery in the Brain Cancer Program at Johns Hopkins. Dr. Holdhoff holds a degree in cello performance from the University of the Arts in Berlin, earned his medical degree from Freie Universität Berlin and received his doctorate degree at Charité University Medicine Berlin, Germany. He trained in internal medicine at Johns Hopkins Bayview Medical Center and in medical oncology at Johns Hopkins Hospital. As a fellow, he trained within the Ludwig Center for Cancer for Cancer Genetics and Therapeutics at Johns Hopkins. Dr. Holdhoff’s research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He is the Director of the Solid Tumor Inpatient Service at the Sidney Kimmel Comprehensive Cancer Center and Director of the Neuro-Oncology Fellowship program at Johns Hopkins.


Samuel J. Klempner, MDSamuel J. Klempner, MD | Massachusetts General Hospital Cancer Center

Dr. Samuel Klempner is a Member of the Faculty at Massachusetts General Hospital and Harvard Medical School and leads the gastric and esophageal program. His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune-mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, the NCI esophagogastric task force, and the NCCN guideline committees for gastric and esophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, and he currently serves as the AGA Research Foundation’s Gastric Cancer Foundation Ben Feinstein Memorial Research Scholar Award in Gastric Cancer. As a member of the gastrointestinal cancer group at MGH Dr. Klempner conducts clinical trials and translational research with new targeted agents and immune therapies and is active in gastroesophageal cancer advocacy and education.


Cornelia Kolberg-Liedtke, MD, PhDCornelia Kolberg-Liedtke, MD, PhD | Universitätsklinikum Essen

Prof. Dr. med. Cornelia Kolberg-Liedtke is a gynecologic oncologist with more than 15 years of experience in the field of clinical and translational research in breast cancer. Her clinical career included positions at the Universities of Muenster and Luebeck, a postdoc period at the MD Anderson Cancer Center and a deputy-chair position at the Department of Gynecology at the Charite, Berlin.

She is co-founder and Managing Director of “Phaon Scientific”, an academic study group focusing on improving treatment strategies through investigator-initiated trials for patients with breast cancer. Furthermore, she holds a position as Senior Vice President for Medical and Scientific Development at “Palleos healthcare”, an international full-service clinical research organization, and as professor at the Department of Gynecology and Obstetrics at the University of Essen, focusing on the coordination of translational research projects in the context of breast cancer clinical trial.

Prof. Kolberg-Liedtke has in-depth knowledge in the field of gynecologic and breast oncology and a strong international research network. She has authored and co-authored more than 100 peer-reviewed publications in the field of breast cancer and received several national and international awards, including a Susan G. Komen for the Cure-AACR Scholar-in-Training Award in 2008, a Basic Science Scholarship at the San Antonio Breast Cancer Symposium in 2009, and an ASCO Merit Award in 2013. She is a member of the AGO (German Association of Gynecological Oncology) Breast Committee, where she contributes to the annual updates for the AGO treatment recommendations for patients with breast cancer.


Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCOThomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO | Duke University School of Medicine

Dr. Thomas W. LeBlanc is Associate Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at the Duke University School of Medicine, and founding Director of the Cancer Patient Experience Research Program (CPEP) in the Duke Cancer Institute. He is board-certified in medical oncology, and in hospice and palliative medicine, and his practice focuses on the care of patients with blood cancers, particularly those with acute leukemias and myelodysplastic syndromes. Dr. LeBlanc’s program of research focuses on palliative care and patient experience issues in hematology.



Emil Lou, MD, PhD, FACPEmil Lou, MD, PhD, FACP | University of Minnesota

Dr. Emil Lou is an Associate Professor in the Department of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. After completing undergraduate studies in biochemistry at SUNY College at Geneseo, Dr. Lou received his M.D. and Ph.D. degrees (Microbiology and Immunology) from SUNY Upstate Medical University in 2004. He performed his residency training in Internal Medicine at Duke University Medical Center and then subsequently completed his Medical Oncology and Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in 2010. He also completed an additional fellowship in Neuro-Oncology at the Preston Robert Tisch Brain Tumor Center at Duke.

Dr. Lou, a diplomate of the American Board of Internal Medicine, is board certified in Medical Oncology and Internal Medicine. In addition he is also board certified in Neuro-Oncology through the United Council for Neurologic Subspecialties. He joined the faculty in the Division of Hematology, Oncology and Transplantation in 2011; since 2019, he has also served as Medical Director of the Clinical Trials Office-Solid Tumor Unit of the Masonic Cancer Center of the University of Minnesota.


Maryam Lustberg, MD, MPHMaryam Lustberg, MD, MPH | Yale School of Medicine

Dr. Maryam Lustberg completed her Medical Oncology fellowship and a Breast Cancer fellowship at The Ohio State University Comprehensive Cancer Center (OSUCCC). During this time, she completed a MPH degree in clinical investigation with a focus in clinical translational research in breast cancer. In her current role, she is the Director of the Breast Center at Yale and Chief of Breast Medical Oncology. Her research focuses on identifying novel genomic predictors as well as blood and imaging biomarkers for treatment toxicity and survivorship management. Dr. Lustberg is currently a member of the ASCO Neuropathy Task Force, co chair of the Alliance Symptom Management Committee and the Alliance Neuropathy Interest Group, and the Chair of the Multinational Association of Supportive Care in Cancer (MASCC) Neurological Complications Committee and President Elect of MASCC. With these efforts, the goal of her research is to identify predictive biomarkers to prevent or lessen treatment-related toxicity and ultimately personalize cancer treatments.


Larissa Meyer, MD, MPHLarissa Meyer, MD, MPH | The University of Texas MD Anderson Cancer Center

Dr. Larissa Meyer is an Associate Professor in the Department of Gynecologic Oncology and Reproductive Medicine with a joint appointment in the Department of Health Services Research at The University of Texas MD Anderson Cancer Center. She is board certified in Gynecologic Oncology and has a Masters of Public Health in Epidemiology. She cares for women with gynecologic malignancies by providing surgical care as well as systemic treatments including chemotherapy, immunotherapy and targeted therapies.

Dr. Meyer’s research focus is to develop and lead multidisciplinary research efforts that aim to improve patient outcomes and decrease disparities through data-driven interventions, improve patient engagement in the shared medical decision process, as well as incorporating the patient’s voice into clinical research and care via patient-reported outcomes.


Jarushka Naidoo, MB BCH MHSJarushka Naidoo, MB BCH MHS | Sidney Kimmel Cancer Center at Johns Hopkins University & Beaumont Hospital/Royal College of Physicians of Ireland

Dr. Jarushka Naidoo is a Consultant Medical Oncologist at Beaumont Hospital/Royal College of Physicians of Ireland; and an Adjunct Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Center for Cancer Immunotherapy, at Johns Hopkins University, in Baltimore, MD.

Dr. Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed both internal medicine training and a medical oncology fellowship through the Royal College of Physicians of Ireland. She then completed an awarded advanced fellowship at Memorial Sloan Kettering Cancer Center (New York), and joined the faculty at Johns Hopkins University in 2015. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related toxicity. She founded and co-chaired the multidisciplinary Johns Hopkins Immune-related Toxicity Team since 2016. Dr. Naidoo currently leads investigator-initiated trials for patients with lung cancer, specifically for those with stage III non-small lung cancer, and those with CNS metastases. She is a leader in the field of immune-related toxicity, having published the first comprehensive analysis of immune-related pneumonitis (Best of J Clin Oncol 2017), bullous pemphigoid (Best of Cancer Immunol Res 2016), and inflammatory arthritis (Ann Rheum Dis 2016). She is the Chair of the Immunotherapy Subcommittee of the US NRG Clinical Trials Cooperative Group, and develops the ASCO, NCCN and SITC Immune-Related Toxicity Guideline Panels. She is the recipient of several grants and awards including a US NIH KL2 Clinical Scholar Award, and a Lung Cancer Foundation of America/IASLC Young Investigator Award on biomarkers of immunotherapy response and toxicity.

Since her return to Ireland (October 2020), she serves as the Chair of the Lung Cancer Disease-specific subgroup (DSSG) of Cancer Trials Ireland, and the Founder and Chair of the Irish national lung cancer research group, the ‘Irish Lung Cancer Alliance.’


Dhaval Shah, MBBS, MDDhaval Shah, MBBS, MD | Helen F. Graham Cancer Center and Research Institute

Dr. Dhaval Shah is a board-certified general medical oncologist and hematologist and currently works at Helen F. Graham Cancer Center and Research Institute in Delaware. He leads the genitourinary multidisciplinary clinic at the cancer center and currently serves as the President of Delaware Society of Clinical Oncology. Dr. Shah completed his medical training at Lokmanya Tilak Municipal Medical College in Mumbai, India. He completed his residency in Internal Medicine at New York Medical College/Westchester Medical Center in 2011. Thereafter, Dr. Shah completed his Fellowship in Hematology/Oncology at Baylor College of Medicine (Houston, TX) in 2014. He served as Chief Fellow during his training there and received the Outstanding Oncology Fellow Award.

Currently, Dr. Shah serves as Medical Director of the Inpatient Oncology Unit at Christiana Hospital in Newark, Delaware. He also serves on the Med Value committee for the hospital system. In addition, he is the GU Pathways director for the US Oncology network. Dr. Shah is also actively involved in the management of his community-based practice and has a Volunteer Clinical Assistant Professor position at Sidney Kimmel Medical College. He is very interested in leadership and healthcare management and is currently pursuing an MBA from Kellogg School of Management.


Rachna T. Shroff, MD, MSRachna T. Shroff, MD, MS | University of Arizona Cancer Center

Dr. Rachna T. Shroff is an Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She is the Director of UACC’s Clinical Trials Office as well as the Director of the Arizona Clinical Trials Network (ACTN). More recently, she was appointed as the Associate Dean for Clinical and Translational Research for UA College of Medicine-Tucson. She came to UACC from MD Anderson Cancer Center in Houston, TX where she was on faculty from 2010-2018 after completing her medical oncology fellowship there.

Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Program Committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.


Jeremy Warner, MD, MS, FAMIA, FASCOJeremy Warner, MD, MS, FAMIA, FASCO | Vanderbilt University

Dr. Jeremy L. Warner is an Associate Professor of Medicine and Biomedical Informatics at Vanderbilt University. He is board-certified in Medical Oncology, Hematology, and Clinical Informatics; his clinical focus is malignant hematology. Dr. Warner is an active member of the American Society of Clinical Oncology (ASCO), where he has served on several committees and is currently an associate editor of JCO Clinical Cancer Informatics. His primary research goal is to make sense of the structured and unstructured data present in electronic health records (EHRs) and clinical knowledge bases. He is the deputy editor of and chief software architect of HemOnc, an ontology focused on capturing all relevant knowledge pertinent to chemotherapy drugs and regimens. He is one of the co-founders of the COVID-19 and Cancer Consortium (CCC19) and maintains the CCC19 registry, which has over 11,000 reports on patients with cancer and COVID-19.


Andrés Wiernik, MD, MBAAndrés Wiernik, MD, MBA | Hospital Metropolitano

Dr. Andrés Wiernik is the Chief Medical Officer (CMO) at Grupo Montecristo Healthcare Division in Costa Rica where he leads a portfolio of healthcare companies including the Hospital Metropolitano healthcare system, the Metropolitano Research Institute and the Medismart health plan. He completed residency training in Internal Medicine at Hennepin County Medical Center in Minneapolis and his fellowship in Hematology and Medical Oncology at the University of Minnesota. He was a staff physician at Hennepin Healthcare from 2013 to 2019 where he was appointed to the Hennepin Healthcare Medical Executive Committee and served on the board of directors of the Minnesota Society of Clinical Oncology for several years. In 2017, he moved to Costa Rica as director of the “Centro de Cáncer y Hematología” at Hospital Metropolitano which is currently the largest multidisciplinary private cancer program in the country. Dr. Wiernik holds an MBA from the University of Chicago.


Marjorie Zauderer, MD, MS, FACPMarjorie Zauderer, MD, MS, FACP | Memorial Sloan Kettering Cancer Center

Dr. Marjorie G. Zauderer is Co-Director of the MSK Mesothelioma Program and Associate Attending on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Zauderer’s clinical practice cares for patients with mesothelioma and lung cancers. Her translational and clinical research, funded by the Department of Defense and National Cancer Institute, focuses on the development of novel therapies for the treatment of mesothelioma. In particular, she has an interest in targeted therapies for malignant mesothelioma. She also works extensively on the identification and development of immunotherapies and biomarkers that may predict response to these new treatments. Dr. Zauderer has also been at the forefront of developing cellular therapies for mesothelioma. She currently serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation.